StockData
Evogene Ltd. logo

Evogene Ltd. (EVGN) stock

EVGNNasdaqAgricultural ChemicalsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026Score 3/30
$0.36−0.03 (-8.70%)

Close on Nov 12, 2026Market cap $3.15MP/E 0.3Yield –

Earnings

Evogene's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2026
$300.00K
-66.7% on a year earlier
EPS, Q2 FY2026
-$0.14
-$0.50 a year earlier
Latest guidance
Issued
Aug 18, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Evogene's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Aug 18, 2026before the open$300.00K-66.7%-$0.14Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026before the open$300.00K-81.3%-$0.61Release
Q2 FY2025ended Jun 30, 2025Aug 19, 2025before the open$900.00K-1.5%-$0.50Release
Q4 FY2024ended Dec 31, 2024Mar 6, 2025before the open$1.60M+176.8%$0.06Release
Q2 FY2024ended Jun 30, 2024Aug 22, 2024before the open$914.00K–-$1.06Release
Q4 FY2023ended Dec 31, 2023Mar 7, 2024before the open$578.00K–-$0.13Release
Q2 FY2023ended Jun 30, 2023Aug 8, 2023before the open–––Release
Q4 FY2022ended Dec 31, 2022Mar 9, 2023before the open–––Release
Q2 FY2022ended Jun 30, 2022Aug 31, 2022before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 10, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Evogene's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
cash usageFY2026$8.50M – $9.50M–NewAug 18, 2026

Guidance history

Every forecast Evogene put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 18, 2026cash usageFY2026$8.50M – $9.50MNew
Aug 22, 2024cash usageFY2024$8.00MLowered
Mar 7, 2024total consolidated burn rateFY2024$21.00MNew
Mar 7, 2024cash usageFY2024$8.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Evogene filed with the SEC as exhibits to Form 8-K or 6-K

  1. the Target Indication for Its Internal
    6-K
  2. 6-K exhibit EX-99.1
    6-K
  3. 6-K exhibit EX-99.2
    6-K
  4. PROXY FOR SPECIAL GENERAL MEETING OF SHAREHOLDERS
    6-K
  5. Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
    6-K
  6. Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.
    6-K
  7. Financial Review and Prospects - Six Months Ended June 30, 2026
    6-K
  8. o o o o o o o o
    6-K
  9. Second Quarter and First Half 2026 Financial Results
    6-K
  10. August 18 , 2026 EARNINGS CALL Q 2 2026
    6-K
  11. 6-K exhibit EX-99.1
    6-K
  12. 6-K exhibit EX-99.2
    6-K
  13. PROXY FOR THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
    6-K
  14. June ˥˪ ͖ 202 6 REAL - WORLD INNOVATION AI - first driven discovery platform for multi - parameter small - molecule generation
    6-K
  15. First Quarter 2026 Financial Results
    6-K

See a number that looks wrong?